Bli medlem
Bli medlem

Du är här


Apricus Biosciences to Present at the 19th Annual BIO CEO & Investor Conference

Annual BIO CEO & Investor Conference

SAN DIEGO, 2017-02-08 13:00 CET (GLOBE NEWSWIRE) --
Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing
innovative medicines in urology and rheumatology, today announced that Richard
Pascoe, Chief Executive Officer, will present at the 19th Annual BIO CEO &
Investor Conference on Tuesday, February 14, 2017, at 9:00 a.m. Eastern Time.
The conference will be held at The Waldorf Astoria, New York, NY. Mr. Pascoe
will provide an update on Vitaros®, the Company's topical treatment for
erectile dysfunction.

A live audio webcast of the presentation can be accessed via the Investor
Relations section of the Company's website at Please log in
approximately 5-10 minutes before the event to ensure a timely connection. A
replay of the webcast will be available for 30 days following the presentation.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing
innovative medicines in urology and rheumatology. Apricus’ commercial product,
Vitaros®, for the treatment of erectile dysfunction, is approved in Canada and
certain countries in Europe, Latin America and the Middle East and is being
commercialized in certain countries in Europe and the Middle East. In September
2015, Apricus in-licensed the U.S. development and commercialization rights for
Vitaros from Allergan. Apricus’ marketing partners for Vitaros include
Recordati Ireland Ltd. (Recordati), Ferring International Center S.A. (Ferring
Pharmaceuticals), Laboratoires Majorelle, Bracco S.p.A., Mylan NV and Elis
Pharmaceuticals Ltd. Apricus currently has one active product candidate,
RayVa™, its product candidate for the treatment of the circulatory disorder
Raynaud’s phenomenon.

For further information on Apricus, visit

*Vitaros® is a registered trademark of NexMed International Limited. Such
trademark is registered in certain countries throughout the world and pending
registration in the United States.


Matthew Beck
The Trout Group
(646) 378-2933

Författare SSE

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.